Rimon Gold Assets Ltd

SEC source: 0001213900-21-014910 · ownership.xml · nonDerivative · entry 1

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,761,199

SEC source: 0001213900-20-045810 · ownership.xml · derivative · entry 12

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 350,334 shares

Expires 2024-12-12

SEC source: 0001213900-20-045810 · ownership.xml · derivative · entry 11

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 520,820 shares

Expires 2021-05-30

SEC source: 0001213900-20-045810 · ownership.xml · derivative · entry 10

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,385,212 shares

Expires 2024-12-12

F6 · derivative.exercise_date: Exercisable five days following the public announcement of positive clinical data results for LO2A.

SEC source: 0001213900-20-045810 · ownership.xml · derivative · entry 9

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 400,000 shares

Expires 2023-10-23

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 8

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,520,077

F5 · kind: On December 29, 2020 the reporting person exercised a warrant to purchase 350,334 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,919 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,415 shares.

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 7

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,522,996

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 6

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,873,330

F4 · kind: On December 29, 2020 the reporting person exercised a warrant to purchase 520,820 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 4,340 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 516,480 shares.

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 5

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,877,670

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 4

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,356,850

F3 · kind: On December 29, 2020 the reporting person exercised a warrant to purchase 3,385,212 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 28,210 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 3,357,002 shares.

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 3

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,385,060

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 2

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,999,848

F2 · kind: On December 29, 2020 the reporting person exercised a warrant to purchase 400,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 3,077 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 396,923 shares.

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-045810 · ownership.xml · nonDerivative · entry 1

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,002,925

F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

SEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 7

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,334

Underlying: Common Stock · 350,334 shares

Expires 2024-12-12

F12 · shares: Future investment rights to purchase 350,334 shares of Common Stock terminated upon the Company paying the remaining aggregate $457,004 outstanding under the 2016 Convertible Notes and the 2017 Convertible Notes.

SEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 6

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,385,212

Underlying: Common Stock · 3,385,212 shares

Expires 2024-12-12

F11 · derivative.exercise_date: Exercisable five days following the public announcement of positive clinical data results for LO2A (such warrants, the "Conversion Warrants").

SEC source: 0001213900-20-002732 · ownership.xml · nonDerivative · entry 2

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,966,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Acquired upon conversion of an aggregate of $457,004 of the 2016 Convertible Notes and the 2017 Convertible Notes at an adjusted conversion price of $0.27 per share.

F8 · balance_after: Represents (i) 2,310,048 shares of Common Stock, (ii) 400,000 shares of Common Stock issuable upon exercise of Series A Warrants, (iii) 3,385,212 shares of Common Stock issuable upon exercise of the Conversion Warrants (as defined below), (iii) 520,820 shares of Common Stock issuable upon exercise of the Loan Extension Warrants (as defined below), and (iv) 350,334 shares of Common Stock issuable upon exercise of Future Investment Rights.

SEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 5

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 520,820

Underlying: Common Stock · 520,820 shares

Expires 2021-05-30

F10 · kind: Issued in consideration for the Reporting Person extending for a term of six months the maturity date of each of the 2016 Convertible Notes and the 2017 Convertible Notes in the aggregate amount of $914,008 (such warrants, the "Loan Extension Warrants").

F10 · price: Issued in consideration for the Reporting Person extending for a term of six months the maturity date of each of the 2016 Convertible Notes and the 2017 Convertible Notes in the aggregate amount of $914,008 (such warrants, the "Loan Extension Warrants").

SEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 4

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires not disclosed

F9 · derivative.expiration_date: The Series B Warrants had a term that expired 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) occurred, the expiration date of the Series B Warrants was to be extended by one day. The Series B Warrants expired on April 24, 2019.

SEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 3

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2023-10-24

SEC source: 0001213900-20-002732 · ownership.xml · nonDerivative · entry 1

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,985,483

F1 · balance_after: Represents (i) 617,442 shares of Common Stock, (ii) 603,486 shares of Common Stock then issuable upon the conversion of the 2016 Convertible Notes (as defined below), (iii) 263,887 shares of Common Stock then issuable upon the conversion of the 2017 Convertible Notes (as defined below), (iv) 400,000 shares of Common Stock then issuable upon exercise of Series A Warrants, (v) 400,000 shares of Common Stock then issuable upon exercise of Series B Warrants, (vi) 392,055 shares of Common Stock then issuable upon the exercise of the 2016 Investment Rights (as defined below) and (vii) 308,613 shares of Common Stock then issuable upon the exercise of the 2017 Investment Rights (as defined below). (Continued in Footnote 2)

F2 · balance_after: (Continued from Footnote 1) The Reporting Person is an Israeli private company wholly owned by the Goldfinger Trust (the "Trust"), whose trustee is Abir Raveh (the "Trustee") and whose beneficiary is Yair Goldfinger. The Trust directs the management of Rimon Gold, its investment and voting decisions and the Trustee directs the management of the Trust, its investment and voting decisions.

F3 · balance_after: (Continued from Footnote 2) The Reporting Person's then-outstanding loan in the principal amount of $531,067, which bore interest at an annual rate of 4% (the "2016 Convertible Notes"), was convertible (including accrued interest) into 605,298 shares of Common Stock based on a conversion price per share of $0.9768. The Reporting Person had the right to invest up to $392,055, in the aggregate, at an agreed price per share of $1.308 (the "2016 Investment Right"). The Reporting Person had the right to invest up to $308,613, in the aggregate, at an agreed price per share of $1.332 (the "2017 Investment Right"). (Continued in Footnote 4)

F4 · balance_after: (Continued from Footnote 3) The Reporting Person's then-outstanding loan to the Issuer in the principal amount of $274,048, which bore interest at an annual rate of 4% (the "2017 Convertible Notes"), was convertible (including accrued interest) into 264,709 shares of Common Stock based on a loan conversion price per share of $1.1112. In connection with a private placement consummated by the Issuer in October 2018, on October 19, 2018 the Reporting Person and the other parties thereto entered into an amendment to the 2016 Convertible Notes and the 2017 Convertible Notes (the "Loan Agreements Amendment"). (Continued in Footnote 5)

F5 · balance_after: (Continued from Footnote 4) Pursuant to the Loan Agreements Amendment, the maturity date (the "Loan Agreements Maturity Date") under the 2016 Convertible Notes and the 2017 Convertible Notes was amended to be the earliest of (a) 90 days following the date that a registration statement relating to the resale of up to 13,706,000 shares of Common Stock issued or issuable in connection with the October 2018 private placement is declared effective by the U.S. Securities and Exchange Commission, (b) 90 days following the date on which all securities issued to investors in the October 2018 private placement are no longer deemed "registrable securities" under the Registration Rights Agreement entered into in connection with the October 2018 private placement, and (c) October 24, 2019. (Continued in Footnote 6)

F6 · balance_after: (Continued from Footnote 5) In addition, pursuant to the Loan Agreements Amendment, the expiration date of the 2016 Investment Right and the 2017 Investment Right was amended to be 180 days after the Loan Agreements Maturity Date.

SEC source: 0001213900-18-005786 · f4032618rimon_wizepharma.xml · derivative · entry 2

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,055

Underlying: Common Stock · 217,442 shares

Expires 2019-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Reporting Person's outstanding loan in the principal amount of $531,067, which bears interest at an annual rate of 4% (the "2016 Convertible Notes"), is convertible (including accrued interest), into 593,925 shares of common stock based on a conversion price per share of $0.9768. Reporting Person has the right, until June 30, 2019, to invest up to $796,601, in the aggregate, at an agreed price per share of $1.308 (the "2016 Investment Right"). Reporting Person 's outstanding loan to the Issuer in the principal amount of $274,048, which bears interest at an annual rate of 4% (the "2017 Convertible Notes") is currently convertible (including accrued interest), into 259,003 shares of common stock based on a loan conversion price per share of $1.1112. The maturity date of the 2016 Convertible Notes and the 2017 Convertible Notes is December 31, 2018. Reporting Person has the right (the "2017 Investment Right") until June 30, 2019, to invest up to $512,187, at a price per share of $1.332.

SEC source: 0001213900-18-005786 · f4032618rimon_wizepharma.xml · nonDerivative · entry 1

Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,770,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The 217,442 shares of common stock of the Issuer were issued upon the exercise of a portion of the 2016 Investment Rights (as defined below).

F2 · balance_after: Represents (i) 217,442 shares of common stock, (ii) 593,925 shares of common stock issuable upon the conversion of the 2016 Convertible Notes (as defined below), (iii) 259,003 shares of common stock issuable upon the conversion of the 2017 Convertible Notes (as defined below), (iv) 392,055 shares of common stock issuable upon the exercise of Reporting Person's 2016 Investment Right (as defined below) and (v) 308,377 shares of common stock issuable upon the exercise of Reporting Person's 2017 Investment Right (as defined below). Reporting Person is an Israeli private company wholly owned by the Goldfinger Trust (the "Trust"), whose trustee is Abir Raveh (the "Trustee") and whose beneficiary is Yair Goldfinger. The Trust directs the management of Reporting Person, its investment and voting decisions and the Trustee directs the management of the Trust, its investment and voting decisions.